Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Company

Illumina Opens First China Manufacturing Base for Gene Sequencers

Fineline Cube Aug 26, 2022

US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking...

Company Drug

Junshi Biosciences Gets NMPA Go-Ahead for TAB009/JS009 Cancer Study

Fineline Cube Aug 26, 2022

Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from the National Medical Products Administration...

Company

Illumina Opens First China Manufacturing Base for Gene Sequencers

Fineline Cube Aug 26, 2022

US-based Illumina (NASDAQ: ILMN) inaugurated its first manufacturing base in China on August 25, marking...

Company

Novartis to Spin Off Sandoz, Focus on Innovative Drugs

Fineline Cube Aug 26, 2022

Swiss drugmaker Novartis announced plans to spin off its generic and biosimilar unit, Sandoz, to...

Company Drug

Clover Biopharmaceuticals’ SCB-2019 Vaccine Proves Effective in Teenagers

Fineline Cube Aug 26, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) announced positive results from a global Phase II/III trial...

Company

CStone Pharmaceuticals’ H1 2022 Revenue Jumps 229% on Drug Sales Growth

Fineline Cube Aug 26, 2022

China-based CStone Pharmaceuticals (HKG: 2616) reported RMB 262 million (USD 49.4 million) in revenue for...

Company

Innovent Biologics’ H1 2022 Revenue Rises 15.3% on Drug Sales Growth

Fineline Cube Aug 26, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) reported RMB 2.24 billion (USD 326.4 million) in revenue...

Company

Akeso Biopharma’s H1 2022 Revenue Rises 26.8% on Penpulimab Sales

Fineline Cube Aug 25, 2022

China-based Akeso Biopharma (HKG: 9926) reported RMB 163 million (USD 23.8 million) in revenue for...

Company Drug

Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases

Fineline Cube Aug 25, 2022

Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III...

Company Deals

eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership

Fineline Cube Aug 25, 2022

Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million...

Company Drug

Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial

Fineline Cube Aug 25, 2022

Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...

Company Deals

Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms

Fineline Cube Aug 25, 2022

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou...

Company Policy / Regulatory

NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall

Fineline Cube Aug 25, 2022

The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution...

Company Deals

Biocytogen and Merck KGaA Ink Global Deal for RenMice Platform Licensing

Fineline Cube Aug 25, 2022

Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has entered into a global...

Company

3SBio Inc. Reports H1 2020 Revenue of RMB 3.091B, Net Profit Up 6.19%

Fineline Cube Aug 25, 2022

China-based 3SBio Inc. (HKG: 1530) reported its H1 2020 financial results, with revenue of RMB...

Company

Betta Pharmaceuticals’ H1 2022 Revenues Rise 8.5% on Drug Sales Growth

Fineline Cube Aug 25, 2022

China’s Betta Pharmaceuticals (SHE: 300558) reported RMB 1.25 billion (USD 182.5 million) in revenue for...

Company Drug

Ranok Therapeutics Doses First Patient in RNK05047 Study for BRD4-Targeted Cancers

Fineline Cube Aug 25, 2022

Ranok Therapeutics Co., Ltd, a Hangzhou-based biotech firm, announced that the first patient has been...

Company Drug

CSPC Pharmaceutical’s SYS6006 mRNA Vaccine Shows Strong Safety and Efficacy in Trials

Fineline Cube Aug 24, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has provided updates on its in-house COVID-19 mRNA...

Policy / Regulatory

China’s Health Commission Promotes Medical-Elderly Care Integration

Fineline Cube Aug 24, 2022

China’s National Health Commission (NHC), National Development and Reform Commission (NDRC), and National Healthcare Security...

Policy / Regulatory

China Passes WHO NRA Evaluation for Vaccine Regulatory System

Fineline Cube Aug 24, 2022

The World Health Organization (WHO) announced that China has successfully passed the evaluation of its...

Posts pagination

1 … 677 678 679 … 711

Recent updates

  • METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines
  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.